Publication | Open Access

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Phase 3Clinical TherapeuticPharmacologyClinical TrialsFirst-line TreatmentPharmacotherapyImmunotherapyMedicineNovel TherapyExtensive-stage Sclc